23 unknown. 23 Phase 2, 7 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Unknown 23 |
| Phase 1 | 7 | Unknown 7 |
| Phase 3 | 4 | Unknown 4 |
Follow Schizophrenia: new trials by email Literature Review of Schizophrenia trials Research Report on Schizophrenia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability, Pharmacokinetics and Efficacy Study of HS-10380 in Patients With Schizophrenia HS-10380, Placebo - Schizophrenia | Phase 1 / Phase 2 | Unknown | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 112 | 2023-07-30 | 2023-07-28 |
| Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Pyridoxine, Cobalamin, Placebo Oral Tablet - Schizophrenia, Drug Induced Movement Disorder, Unspecified | Phase 2 / Phase 3 | Unknown | Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara | 45 | 2019-09-03 | 2019-12-18 |
| Pentoxifylline Add-on Therapy for Schizophrenia Oxopurin - Schizophrenia | Phase 1 / Phase 2 | Unknown | Mazra Mental Health Center | 90 | 2019-04-20 | 2021-10-11 |
| Add-on Methotrexate for the Treatment of Schizophrenia Methotrexate, Placebo Arm - Schizophrenia | Phase 2 | Unknown | Sheba Medical Center | 100 | 2017-12-15 | 2017-12-12 |
| Siltuximab in Schizophrenia Siltuximab, normal saline - Schizophrenia, Psychotic Disorders | Phase 1 / Phase 2 | Unknown | Brian Miller | 30 | 2016-05-01 | 2023-07-21 |
| rTMS Treatment for Positive and Negative Symptoms of Schizophrenia rTMS - Schizophrenia | Phase 2 / Phase 3 | Unknown | St. Joseph's Healthcare Hamilton | 20 | 2016-02-01 | 2019-04-22 |
| Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination Direct Current Stimulation, Dextromethorphan - Schizophrenia | Phase 1 / Phase 2 | Unknown | University of Ottawa | 12 | 2015-04-01 | 2015-04-27 |
| Evaluation of Tolcapone as a Cognitive Enhancer in Schizophrenia Tolcapone - Schizophrenia | Phase 2 | Unknown | Clinica Universidad de Navarra, Universidad de Navarra | 20 | 2014-09-22 | 2024-04-29 |
| Famotidine in Schizophrenia Famotidine, Placebo - Schizophrenia | Phase 2 / Phase 3 | Unknown | Jesper Ekelund | 140 | 2014-03-01 | 2015-04-14 |
| The Role of miR-30 Family Dysregulation in Response to Antipsychotic Treatment Risperidone, Olanzapine, Quetiapine - Schizophrenia | Phase 1 / Phase 2 | Unknown | Shanxi Medical University | 200 | 2013-01-01 | 2016-01-08 |
| N-methyl-D-aspartic Acid (NMDA) and Cognitive Remediation in Schizophrenia D-serine, placebo, Sensory Based remediation paradigm - Schizophrenia, Schizoaffective Disorder | Phase 2 | Unknown | Nathan Kline Institute for Psychiatric Research | 16 | 2012-03-01 | 2012-10-25 |
| High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia D-serine - Schizophrenia | Phase 2 | Unknown | Hadassah Medical Organization | 54 | 2011-11-01 | 2011-10-25 |
| Repetitive Transcranial Magnetic Stimulation and Intermittent Theta Burst (iTBS) in Schizophrenia repetitive Transcranial Magnetic Stimulation (Magstim rapid2 ), repetitive Transcranial Magnetic Stimulation (Magstim rapid2), repetitive Transcranial Magnetic Stimulation(Magstim rapid2) - Schizophrenia | Phase 2 | Unknown | University of Tehran | 30 | 2011-01-01 | 2015-09-01 |
| Is MS14 Helpful in Schizophrenia? MS14, Risperidone - Schizophrenia | Phase 2 | Unknown | Farzan Institute | 50 | 2010-02-01 | 2010-03-09 |
| The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia Suo Quan Wan, Wu Lin San, Placebo - Schizophrenia, Clozapine | Phase 2 | Unknown | Taichung Veterans General Hospital | 45 | 2010-01-01 | 2010-01-14 |
| Transcranial Magnetic Stimulation (TMS) in Schizophrenia DEEP TMS H1 coil, Deep H1 coil TMS - Schizophrenia | Phase 2 / Phase 3 | Unknown | BeerYaakov Mental Health Center | 20 | 2008-10-01 | 2010-03-03 |
| A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients MEM 3454, Placebo for MEM 3454 - Schizophrenia | Phase 2 | Unknown | Memory Pharmaceuticals | 12 | 2008-08-01 | 2008-07-31 |
| A Double-Blind, Controlled Study of Aripiprazole in Co-Morbid Schizophrenia and Cocaine Dependence Aripiprazole, Perphenazine - Schizophrenia, Cocaine Dependence | Phase 2 | Unknown | Paul Saenger | 44 | 2008-08-01 | 2012-09-07 |
| The Effect of Intranasal Administration of Oxytocin on Empathic Abilities. Oxytocin (also: syntocinon, pitocin), Placebo - Schizophrenia | Phase 2 | Unknown | Shalvata Mental Health Center | 100 | 2008-05-01 | 2009-02-05 |
| Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis modified cognitive behavioural therapy (mCBT) - Psychotic Disorders, Schizophrenia | Phase 2 | Unknown | University of Cologne | 42 | 2007-05-01 | 2009-02-20 |
Showing 20 of 23. Sign in to see all of them.
Psychotic Disorders (5) · Cocaine-Related Disorders (1) · Inflammation (1) · Medication Adherence (1) · Schizophrenia, Paranoid (1) · Sialorrhea (1)
Mental Disorders (23) · Schizophrenia Spectrum and Other Psychotic Disorders (23) · Behavior (1) · Chemically-Induced Disorders (1) · Health Behavior (1) · Mouth Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Patient Acceptance of Health Care (1) · Patient Compliance (1) · Salivary Gland Diseases (1) · Stomatognathic Diseases (1) · Substance-Related Disorders (1) · Treatment Adherence and Compliance (1)
Aripiprazole (2) · Risperidone (2) · Dextromethorphan (1) · Drug Evaluation (1) · Famotidine (1) · Methotrexate (1) · Olanzapine (1) · Oxytocin (1) · Pentoxifylline (1) · Perphenazine (1) · Pyridoxine (1) · Quetiapine Fumarate (1) · Saline Solution (1) · Tolcapone (1) · Transcranial Direct Current Stimulation (1)
Sheba Medical Center (2) · BeerYaakov Mental Health Center (1) · Brian Miller (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Farzan Institute (1) · Hadassah Medical Organization (1) · Herzog Hospital (1) · Jesper Ekelund (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Lady Reading Hospital, Pakistan (1) · Mazra Mental Health Center (1) · Memory Pharmaceuticals (1) · Nathan Kline Institute for Psychiatric Research (1) · Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara (1) · Paul Saenger (1)
Israel (6) · United States (4) · Canada (2) · Iran (2) · Brazil (1) · China (1) · Finland (1) · Germany (1) · Pakistan (1) · Spain (1) · Sweden (1) · Taiwan (1)
Amit Lotan, MD (1) · Andreas Bechdolf, PD Dr. (1) · Ann Olincy, MD, MPH (1) · Bernard Lerer, MD (1) · Danielle Impey, Ph.D. (cand.) (1) · Gary Chaimowitz, MD, FRCPC (1) · Jesper Ekelund, MD, PhD (1) · Joshua T Kantrowitz, MD (1) · Lia LO Sanders, MD, PhD (1) · Mark Weiser, MD (1) · Oded Rosenberg, M.D. (1) · Patricio Molero, MD, PhD (1) · Pesach Lichtenberg, M.D. (1) · Saeed Farooq, MCPS,FCPS (1) · Seyed Vahid Shariat (1)